Evidence map›Paper›PMID 34938162›Full record

ArticleFrontiers in cellular neuroscience2021

Neural Progenitor Cells Expressing Herpes Simplex Virus-Thymidine Kinase for Ablation Have Differential Chemosensitivity to Brivudine and Ganciclovir.

Zijian Lou, Alexander Post, Christopher E Rodgers, Mahmood Chamankhah, James Hong, Christopher S Ahuja, Mohamad Khazaei, Michael G Fehlings

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cellular neuroscience, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Zijian LouDivision of Genetics and Development, Krembil Research Institute, University Health Network, Toronto, ON, Canada.
Alexander PostDivision of Genetics and Development, Krembil Research Institute, University Health Network, Toronto, ON, Canada.
Christopher E RodgersDivision of Genetics and Development, Krembil Research Institute, University Health Network, Toronto, ON, Canada.
Mahmood ChamankhahDivision of Genetics and Development, Krembil Research Institute, University Health Network, Toronto, ON, Canada.
James HongDivision of Genetics and Development, Krembil Research Institute, University Health Network, Toronto, ON, Canada.
Christopher S AhujaDivision of Genetics and Development, Krembil Research Institute, University Health Network, Toronto, ON, Canada.
Mohamad KhazaeiDivision of Genetics and Development, Krembil Research Institute, University Health Network, Toronto, ON, Canada.
Michael G FehlingsDivision of Genetics and Development, Krembil Research Institute, University Health Network, Toronto, ON, Canada.
University Health Network · CAUniversity of Toronto · CAKrembil Research Institute

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neural progenitor cell (NPC) transplants are a promising therapy for treating spinal cord injury (SCI), however, their long-term role after engraftment and the relative contribution to ongoing functional recovery remains a key knowledge gap. Selective human cell ablation techniques, currently being developed to improve the safety of progenitor cell transplant therapies in patients, may also be used as tools to probe the regenerative effects attributable to individual grafted cell populations. The Herpes Simplex Virus Thymidine Kinase (HSV-TK) and ganciclovir (GCV) system has been extensively studied in the context of SCI and broader CNS disease. However, the efficacy of brivudine (BVDU), another HSV-TK prodrug with potentially reduced bystander cytotoxic effects and

Indexed as

brivudinecell ablationganciclovirinduced pluripotent stem cellsneural progenitor cellspinal cord injury

Identifiers

PMID34938162
PMCPMC8685296
OpenAlexW4200319389

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.